ECOSTRATAR PLATFORM

Our technology is chemically designed to respond to acidic cellular environments, such as those found in inflammation associated with diseases like cancer, arteriosclerosis, viral and bacterial infections, and neurological disorders.

The nanocarrier features a carefully selected set of intermediates that create an amphiphilic and amphoteric surface, remaining neutral and hydrophilic while circulating in the bloodstream or within healthy tissues (pH 7.2–7.5), but becoming cationic in environments with a pH below 6.5. This molecular shift promotes accumulation in acidic microenvironments and facilitates preferential internalization into affected cells.

Additionally, the nanocapsule wall is designed with specific functional groups that are degraded by enzymes overexpressed in infected cells, ensuring precise and controlled drug release at the target site. These nanocapsules can also be synthesized with multi-walled functional structures, enabling the simultaneous encapsulation of both hydrophilic and hydrophobic drugs. This unique capability not only enhances drug stability and bioavailability but also fosters the discovery of new synergistic effects between different therapeutic agents.

Our studies show that these self-dispersing nanocapsules selectively target dysregulated cells and inflammation zones without the need for external surfactants, eliminating associated toxicity and immunogenicity risks. They are also biocompatible, biobased, and biodegradable, ensuring safe integration and metabolization within biological systems.

With no observed toxicity in in vitro and in vivo studies, this platform opens new avenues for the selective delivery of diverse drug combinations in a fully water-based system, paving the way for next-generation therapeutic solutions.

Polar NanoPharma is a spin-out of Ecopol Tech, created to transform oncology treatments with its exclusive application of ECOSTRATAR technology. This innovative drug delivery platform enables precise, efficient, and safer drug release—minimizing systemic side effects while maximizing therapeutic impact. By enhancing drug solubility, stabilizing active compounds, and optimizing the therapeutic index, ECOSTRATAR unlocks new possibilities for advanced safer cancer treatments.

 By leveraging ECOSTRATAR’s groundbreaking nanotechnology, Polar NanoPharma aims to bring multiple oncology drug candidates into clinical phases, optimizing precision medicine approaches to revolutionize cancer treatment and improve patient outcomes.

Beyond its numerous advantages, this cutting-edge technology also opens new possibilities for drug synergy, potentially enhancing the safety and effectiveness of combination therapies.

This marks a significant advancement in translating nanotechnology into real-world clinical applications, reinforcing our mission to push the boundaries of pharmaceutical innovation.